Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential

Leukemia and Lymphoma

Volumn 56, Issue 1, 2015, Pages 219-225

  Ito, Daisuke ^a,b   Brewer, Susan ^c   Modiano, Jaime F ^a,b   Beall, Melissa J ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c IDEXX LABORATORIES   (United States)

Author keywords

B cell lymphoma; CD20; Dogs; Monoclonal antibody; Phagocytosis

Indexed keywords

CD20 ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN BINDING;

AMINO ACID SEQUENCE; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; B LYMPHOCYTE; CELL LINE; CHEMISTRY; DIAGNOSTIC USE; DOG; HUMAN; IMMUNOLOGY; LYMPHOMA, B-CELL; MACROPHAGE; METABOLISM; MOLECULAR GENETICS; MOUSE; PATHOLOGY; PHAGOCYTOSIS; PROTEIN DOMAIN; SEQUENCE ALIGNMENT; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; B-LYMPHOCYTES; CELL LINE; CELL LINE, TUMOR; DOGS; HUMANS; LYMPHOMA, B-CELL; MACROPHAGES; MICE; MOLECULAR SEQUENCE DATA; PHAGOCYTOSIS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; SEQUENCE ALIGNMENT;

EID: 84922350495     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.914193     Document Type: Article

References (26)

1. Modiano JF, Breen M, Burnett RC, et al. Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. Cancer Res 2005;65:5654-5661.
2. Chun R. Lymphoma: which chemotherapy protocol and why? Top Companion Anim Med 2009; 24: 157-162.
3. Modiano JF, Breen M, Valli VE, et al. Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non-Hodgkin's lymphoma. Leukemia 2007;21:184-187.
4. Frantz AM, Sarver AL, Ito D, et al. Molecular prof ling reveals prognostically signif cant subtypes of canine lymphoma. Vet Pathol 2013;50:693-703.
5. Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002; 16: 704-709.
6. MacDonald VS, Tamm DH, Kurzman ID, et al. Does L-asparaginase inf uence ef cacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma? J Vet Intern Med 2005;19:732-736.
7. Vail DM, Pinkerton MM, Young KM. Canine lymphoma and lymphoid leukemia. In: Withrow SJ, Vail DM, Page RL, editors. Withrow and MacEwen's small animal clinical oncology. 5th ed. St. Louis: Saunders; 2012. pp 608-638.
8. Traullé C, Coifer BB. Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma. Future Oncol 2005; 1:297-306.
9. Jubala CM, Wojcieszyn JW, Valli VEO, et al. CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma. 2005;42:468-476.
10. Impellizeri JA, Howell K, McKeever KP, et al. The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation. Vet J 2006;171:556-558.
11. Rütgen BC, Hammer SE, Gerner W, et al. Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring dif use large cell lymphoma. Leuk Res 2010;34:932-938.
12. Harlow E, Lane D. Antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1988. pp 139-318.
13. Ito D, Endicott MM, Jubala CM, et al. A tumor-related lymphoid progenitor population supports hierarchical tumor organization in canine B-cell lymphoma. J Vet Intern Med 2011;25:890-896.
14. Ito D, Frantz AM, Williams C, et al. CD40 ligand is necessary and suf cient to support primary dif use large B-cell lymphoma cells in culture: a tool for in vitropreclinical studies with primary B-cell malignancies. Leuk Lymphoma 2012;53:1390-1398.
15. Ernst JA, Li H, Kim HS, et al. Isolation and characterization of the B-cell marker CD20. Biochemistry 2005;44:15150-15158.
16. Binder M, Otto F, Mertelsmann R, et al. The epitope recognized by rituximab. Blood 2006;108:1975-1978.
17. Perosa F, Favoino E, Caragnano MA, et al. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood 2006;107:1070-1077.
18. Du J, Wang H, Zhong C, et al. Structural basis for recognition of CD20 by therapeutic antibody rituximab. J Biol Chem 2007; 282: 15073-15080.
19. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994; 15: 450-454.
20. Hultin LE, Hausner MA, Hultin PM, et al. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry 1993; 14: 196-204.
21. Buckner CL, Christiansen LR, Bourgeois D, et al. CD20 positive T-cell lymphoma/leukemia: a rare entity with potential diagnostic pitfalls. Ann Clin Lab Sci 2007;37:263-267.
22. Dotan E, Aggarwal C, Smith MR. Impact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin's lymphoma. 2010;35:148-157.
23. Lim SH, Beers SA, French RR, et al. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2010; 95:135-143.
24. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793-1800.
25. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362-371.
26. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010;47:115-123.